RemeGen Co., Ltd. (688331.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 115.10

From 52W high−21.55%

Volume5.20M

Market capCNY 65.72B

P/E (TTM)92.6x

P/S (TTM)19.2x

Div yield—

Key dataSep 18, 2026

Open

CNY 115.10

From 52W high

−21.55%

Volume

5.20M

Market cap

CNY 65.72B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

66.5x

P/E (TTM)

92.6x

RSI (14)

42.5

MomentumView details →

1D Return

−7.24%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

92.6x

EV/EBITDA

66.5x

EV/Sales

19.4x

P/S (TTM)

19.2x

P/B (TTM)

16.7x

ProfitabilityView details →

Gross Margin

86.91%

Net Margin

38.20%

EBITDA Margin

29.15%

ROE (TTM)

32.88%

ROA (TTM)

17.54%

Asset Turnover

0.46x

GrowthView details →

Revenue YoY

+76.81%

EPS YoY

+191.52%

FCF YoY

+103.97%

Revenue CAGR 3Y

+61.48%

EPS CAGR 3Y

+147.25%

EBITDA YoY

—

MomentumView details →

1D Return

−7.24%

YTD Return

—

1Y Return

—

RSI (14)

42.5

vs 50D SMA

−6.79%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.46x

Current Ratio

1.58x

Quick Ratio

1.31x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

CNY 7.74

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

91.46%

Financials snapshotView financials →

Revenue (TTM)

7.98B

Net Income (TTM)

5.80B

Op. CF (TTM)

4.50B

Next earningsNov 4, 2026 →

Latest newsMore news →

RemeGen Co., Ltd. repurchased 19,000 A-shares on the Shanghai Stock Exchange via centralized bidding on September 11, 2026, at RMB 113.2-113.7 per share for a total of RMB 2.1552 million, to be used for an employee equity incentive plan.9d ago

China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.20d ago

Similar companies

argenx SEARGX Moderna, Inc.MRNA Encell Co. Ltd.456070.KQ Asymchem Laboratories (Tianjin) Co., Ltd.06821.HK Regeneron Pharmaceuticals, Inc.REGN Pharmaron Beijing Co., Ltd.03759.HK Find similar companies →

Latest newsMore news →

RemeGen Co., Ltd. repurchased 19,000 A-shares on the Shanghai Stock Exchange via centralized bidding on September 11, 2026, at RMB 113.2-113.7 per share for a total of RMB 2.1552 million, to be used for an employee equity incentive plan.9d ago China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.20d ago